Journal of Antimicrobial Chemotherapy最新文献

{"title":"Vancomycin-resistant Enterococcus prevalence and its association along the food chain: a systematic review and meta-analysis.","authors":"Benjamin Caddey, Waseem Shaukat, Karen L Tang, Herman W Barkema","doi":"10.1093/jac/dkaf008","DOIUrl":"10.1093/jac/dkaf008","url":null,"abstract":"<p><strong>Background: </strong>Vancomycin-resistant Enterococcus (VRE) are present across the One Health continuum and pose a considerable risk for transmission along the food chain. This systematic review and meta-analysis estimates the prevalence of VRE colonization in livestock, food of animal origin, and in human populations.</p><p><strong>Methods: </strong>Embase, MEDLINE and CAB Abstracts were searched for eligible literature. A total of 54 manuscripts passed inclusion criteria by providing prevalence estimates of VRE in a human population and at least one of either livestock or food. Random effects meta-analysis was conducted to determine prevalence estimates, and risk of bias in pooled estimates was assessed using funnel plots and Egger regression.</p><p><strong>Results: </strong>Global pooled prevalence of VRE colonization was highest in poultry and poultry meat at 16% (95% CI: 6%-28%) and 15% (95% CI: 1%-39%), respectively. Human-associated VRE colonization was highest in livestock workers, with a pooled prevalence of 11% (95% CI: 2%-25%), and lowest in the general public at 2% (95% CI: 0%-3%). Meta-regression demonstrated that human VRE prevalence increased at a rate of 0.75% (95% CI: 0.46%-1.04%; P < 0.001) per 1% increase in livestock VRE colonization.</p><p><strong>Conclusions: </strong>This meta-analysis established a clear link of VRE across One Health sectors. VRE colonization is likely elevated for those in contact with colonized animals or contaminated food products. Quality of evidence in pooled prevalence estimates was limited by publication bias and heterogeneity. The results of this study enhance calls for a One Health approach for mitigating the global burden of priority antimicrobial resistance pathogens.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":"908-918"},"PeriodicalIF":3.9,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11962378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143028840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emergence of MRSA ST612 in horses and of MSSA CC398 in cats in France.","authors":"Marisa Haenni, Séverine Murri, Antoine Drapeau, Iarimino Rafidinarivo, Stéphanie Gilles, Nicolas Keck, Albertine Léon, Aline Sulter, Marie-Capucine Tricaud, Pauline François, Jean-Yves Madec","doi":"10.1093/jac/dkaf027","DOIUrl":"10.1093/jac/dkaf027","url":null,"abstract":"<p><strong>Objectives: </strong>Staphylococcus aureus is an important zoonotic pathogen that has often been seen in animals through the prism of the MRSA clonal complex (CC) 398 in pigs and in-contact humans. The goal of this study was first to assess the prevalence of MRSA, and second to look for MSSA CC398 in cats, dogs and horses in France.</p><p><strong>Methods: </strong>Clinical S. aureus isolates (n = 479) were collected from 186 cats, 143 dogs and 150 horses during 2022-2023 all over the French territory. Antibiograms were performed on all isolates. MRSA and MSSA CC398 isolates were subject to WGS. Core genome (cg) MLST-based and SNP-based phylogenetic analyses were performed using published methodologies, and characterization of the isolates was performed using publicly available tools.</p><p><strong>Results: </strong>Sixty-six MRSA isolates were identified in 14 cats (7.5%), 9 dogs (6.3%) and 43 horses (28.7%). The epidemiology of MRSA in cats and dogs remained stable since a previous study in 2015, with the presence of both CC398 and human-associated clones. In horses, in contrast, an important increase in MRSA (from 10% to 28.7%) was observed, potentially attributable to the emergence of the ST612 clones. In parallel, CC398 MSSA, a clone usually described as animal-independent, was found in 24.2% of the cat isolates.</p><p><strong>Conclusions: </strong>Our study, which is leading the way to a genomic surveillance of S. aureus in France, revealed the emergence of both MRSA ST612 in horses and MSSA CC398 in cats. These clones should be closely monitored to avoid their zoonotic spread and to understand their dynamics of transmission between humans and animals.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":"1001-1010"},"PeriodicalIF":3.9,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia-authors' response.","authors":"Thomas P C Dorlo, Wan-Yu Chu","doi":"10.1093/jac/dkaf059","DOIUrl":"10.1093/jac/dkaf059","url":null,"abstract":"","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":"1162-1164"},"PeriodicalIF":3.9,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fluconazole step-down therapy versus echinocandins for the treatment of Candida glabrata invasive candidiasis with candidaemia.","authors":"Madeline Droney, Erica Reed, Sajed Sarwar, Kelci Coe, Nikki Tran","doi":"10.1093/jac/dkaf026","DOIUrl":"10.1093/jac/dkaf026","url":null,"abstract":"<p><strong>Objectives: </strong>Candida glabrata is the second most common species responsible for invasive candidiasis, including candidaemia. Echinocandins are typically the first-line therapy for C. glabrata candidaemia, with the option to transition to oral fluconazole. Studies are needed to evaluate clinical outcomes in patients initially treated with echinocandins then transitioned to fluconazole.</p><p><strong>Methods: </strong>This was a retrospective, single-centre cohort study of patients with C. glabrata candidaemia from November 2011 to August 2023. Inpatients aged 18-89 years who received an echinocandin within 24 h of the initial positive blood culture were included. Patients were excluded if they received antifungal treatment less than 48 h, combination therapy, or fluconazole as initial therapy. The primary composite outcome was 30-day clinical failure.</p><p><strong>Results: </strong>A total of 186 patients were included (n = 153 echinocandin only; n = 33 fluconazole step-down). The most common source of candidaemia was line-associated in both groups with the majority having source control (43% echinocandin versus 58% fluconazole; P = 0.32). Compared to fluconazole, patients in the echinocandin group had a higher rate of concomitant bacteraemia (45% versus 24%; P = 0.03) and endovascular complications (11% versus 0%; P = 0.05). There was no significant difference in treatment duration between echinocandin and fluconazole (16 versus 19 days; P = 0.46), incidence of persistent candidaemia (22% versus 24%; P = 0.7), or 30-day clinical failure (15% versus 9%; P = 0.58).</p><p><strong>Conclusions: </strong>Fluconazole appears to be a safe and reasonable step-down therapy in the management of C. glabrata candidaemia.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":"996-1000"},"PeriodicalIF":3.9,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11962369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External quality assurance (EQA) network in South and South-East Asia: experience and results from an international EQA programme in One Health sector reference laboratories.","authors":"Tomislav Kostyanev, Hiba Al-Mir, Kristi Prifti, Lone Brink Rasmussen, Freshwork Ayalew Abegaz, Patrícia Teixeira Dos Santos, Soo-Young Kwon, Rangsiya Prathan, Taradon Luang Tongkum, Pattrarat Chanchaithong, Pitak Santanirand, Watcharaporn Kamjumphol, Ondari D Mogeni, Tobin Guarnacci, Nimesh Poudyal, Marianne Holm, Wantana Paveenkittiporn, Rungtip Chuanchuen, Rene S Hendriksen","doi":"10.1093/jac/dkaf032","DOIUrl":"10.1093/jac/dkaf032","url":null,"abstract":"<p><strong>Objectives: </strong>External quality assurance (EQA) is an objective tool to assess laboratories' diagnostic performance and their adherence to recognized international standards. External Quality Assessment in Asia (EQASIA) is an EQA network in South and South-East Asia established in 2020 with the aim of improving the quality of bacteriology diagnostics across all One Health sectors in the region. The aim of this paper is to provide a comprehensive overview of the EQA results collected from the EQASIA network and to assess improvements among the participating laboratories.</p><p><strong>Methods: </strong>Six EQA rounds were conducted between 2021 and 2023, each composed of different panels of WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) and The Food and Agriculture Organization of the United Nations (FAO) priority pathogens of interest to both the human and animal health sector.</p><p><strong>Results: </strong>Between 24 and 32 laboratories signed up for six EQA rounds (EQA1-6). Participating laboratories were able to isolate and correctly identify most of the isolates across the EQA panels except for the Campylobacter spp. and Enterococcus spp. panels. The overall performance of laboratories across the six EQAs was between 75% and 100% (average 93.3% and median 93.6%). The obtained results showed a significant improvement in laboratories' performance over time.</p><p><strong>Conclusions: </strong>Laboratory capacity development and quality assurance in a microbiology laboratory are of particular importance especially in the context of antimicrobial resistance (AMR) and One Health surveillance. The EQASIA programme has the potential to validate laboratories' performance in detecting important One Health pathogens, generating reliable data for effective surveillance to curb AMR.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":"1037-1046"},"PeriodicalIF":3.9,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11962387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual versus sequenial therapy using rifaximin and MTZ in a patient with intestinal methanogen overgrowth-a case report.","authors":"Gernot Kriegshäuser","doi":"10.1093/jac/dkaf107","DOIUrl":"https://doi.org/10.1093/jac/dkaf107","url":null,"abstract":"","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cross-resistance to 14-, 15- and 16-membered ring macrolides in Salmonella and Campylobacter.","authors":"Ruby Singh, Sampa Mukherjee, Lucas B Harrision, Patrick F McDermott, Beilei Ge, Jeffrey M Gilbert, Cong Li, Jean M Whichard, Gamola Z Fortenberry, Uday Dessai, Shaohua Zhao","doi":"10.1093/jac/dkaf094","DOIUrl":"https://doi.org/10.1093/jac/dkaf094","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to gain a better understanding of how resistance determinants in Salmonella and Campylobacter contribute to 14-, 15- and 16-membered ring macrolide resistance phenotypes.</p><p><strong>Methods: </strong>A total of 126 azithromycin-resistant (AziR) and -susceptible (AziS) [Salmonella (n = 45) and Campylobacter (n = 81)] isolates were selected for antimicrobial susceptibility testing (AST) and WGS.</p><p><strong>Results: </strong>Seven functional macrolide resistance determinants, including erm(42), mef(C), mph(A), mph(E), mph(G), msr(E) and one point mutation (acrB_R717L) were previously identified in AziR  Salmonella. These determinants resulted in an 8- and 16-fold 15-membered ring gamithromycin and azithromycin MIC50 increase, respectively, compared with AziS isolates, with a maximum MIC increase of up to 256. The same isolates also exhibited up to a 32-fold 14-membered ring erythromycin MIC50 increase. Salmonella with erm(42) or acrB_R717L showed up to 128-fold 16-membered ring macrolide tildipirosin MIC increase, compared with isolates that were susceptible or carrying other macrolide resistance genes. In Campylobacter, all AziR isolates had an MIC50 ranging from 32 to 4096 mg/L of the various membered ring macrolides, whereases all susceptible Campylobacter isolates had significantly lower MIC50 values, ranging from 0.25 to 4 mg/L. The MIC50 of the various ring macrolides for AziR  Campylobacter isolates was 16- to 4096-fold higher when compared with AziS  Campylobacter.</p><p><strong>Conclusions: </strong>Our study has revealed that the function of macrolide resistance genes in Salmonella can be associated with specific macrolide ring structures, whereas the single 23S rRNA mutation in Campylobacter results in significantly elevated MICs of all macrolides. for the various ring macrolides.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pandemic human-associated extended-spectrum β-lactamase-producing Escherichia coli lineages of ST38, ST131 and ST141 identified in Viennese dogs.","authors":"Pia Saria, Pavlos G Doulidis, Amélie Desvars-Larrive, Adrienn Gréta Tóth, Iwan A Burgener, Alexandro Rodríguez-Rojas, Olga Makarova","doi":"10.1093/jac/dkaf103","DOIUrl":"https://doi.org/10.1093/jac/dkaf103","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the prevalence of ESBL Enterobacteriaceae among dogs attending a veterinary clinic in Vienna, characterize the isolates in terms of antimicrobial resistance, virulence and phylogenetic relationships.</p><p><strong>Methods: </strong>Faecal samples of 88 dogs were streaked on selective plates, species were identified by MALDI-ToF MS, tested for resistance by a combination disk test and VITEK 2®, whole genome-sequenced, bioinformatically genotyped, phylogenetically analysed and screened for resistance and virulence genes.</p><p><strong>Results: </strong>ESBL Escherichia coli carriage rate was 14.8% (95% CI: [8.1-23.9]). No carbapenem resistance was found, but 53.8% of the isolates were classified genotypically as multi-drug resistant. Phylogenetic analyses revealed that half of the isolates belonged to animal and environment-associated phylogroups, while another half was human-associated, and included high-risk international clones of ST38, ST131 and ST141, which clustered primarily with human isolates. All isolates harboured various virulence-associated genes, including four isolates that encoded exotoxins, of which two were from the pandemic ST131 and emerging ST141 lineages.</p><p><strong>Conclusions: </strong>Dogs in Vienna carry ESBL E. coli with high rates of multi-drug resistance and virulence, and a highly diverse population structure that includes pandemic human-associated lineages.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Appropriateness of loading dose and TDM in patients treated with teicoplanin: a single-centre observational retrospective cohort study comparing single-daily and thrice-weekly regimens.","authors":"Alessandra Helen Behring, Chiara Mariani, Martina Gerbi, Martina Offer, Maddalena Matone, Dario Cattaneo, Andrea Giacomelli, Marta Colaneri, Riccardo Giorgi, Stefania Merli, Stefania Piconi, Spinello Antinori, Andrea Gori, Matteo Passerini","doi":"10.1093/jac/dkaf097","DOIUrl":"https://doi.org/10.1093/jac/dkaf097","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the appropriateness of teicoplanin loading dose and therapeutic drug monitoring (TDM) in single-daily regimen (SDR) versus thrice-weekly regimen (TWR), and to compare safety and effectiveness.</p><p><strong>Methods: </strong>This single-centre observational retrospective cohort study included adult patients treated with TDM-based teicoplanin for infections between April 2015 and December 2021. Appropriateness of loading dose and TDM, adverse events (AEs) and clinical outcomes were evaluated. A post hoc analysis assessed achievement of target TDM concentrations following appropriate loading dose.</p><p><strong>Results: </strong>Among 183 patients (103 SDR, 80 TWR), appropriate loading doses were less frequent in the SDR group [33/103 (35.9%, missing = 11) versus 56/80 (72.7%, missing = 3); P < 0.001]. First TDM was less commonly performed as recommended in the SDR group on Day 4 [89/103 (86.4%) versus 79/80 (98.8%); P = 0.002] and on Day 7 [31/103 (30.1%) versus 47/80 (58.8%); P < 0.001]. No significant differences were observed in AEs [15/103 (14.6%) versus 8/80 (10%); P = 0.38] or clinical success [60/103 (58.3%) versus 49/80 (61.3%); P = 0.681] between groups. Post hoc analysis showed that 2/16 (13%) patients with deep infections and 9/11 (82%) with non-deep infections on a TWR achieved target concentrations after loading dose.</p><p><strong>Conclusions: </strong>Higher adherence to loading dose and TDM recommendations was observed for TWR compared with SDR. However, the TWR often failed to achieve adequate TDM levels for higher targets, highlighting the need for optimized TWR loading dose strategies.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of obesity on clinical outcomes in patients treated with ceftobiprole: results from Phase 3 clinical trials.","authors":"Thomas L Holland, Andrew F Shorr, J Scott Overcash, Marc Engelhardt, Mark Jones, Daniel Ionescu, Karine Litherland, Mikael Saulay, Vance G Fowler","doi":"10.1093/jac/dkaf096","DOIUrl":"https://doi.org/10.1093/jac/dkaf096","url":null,"abstract":"<p><strong>Background: </strong>Ceftobiprole was non-inferior to comparators for the treatment of Staphylococcus aureus bloodstream infection (bacteraemia) (SAB), acute bacterial skin and skin structure infection (ABSSSI), and community-acquired bacterial pneumonia (CABP), leading to regulatory approval for these indications. Whether dosing should be modified for patients with obesity is unknown.</p><p><strong>Objectives: </strong>This post hoc analysis evaluated the relationship of obesity and clinical outcomes in patients treated with ceftobiprole for SAB, ABSSSI or CABP.</p><p><strong>Methods: </strong>Efficacy and safety outcomes were assessed based on BMI from three registrational clinical trials that evaluated ceftobiprole against comparators.</p><p><strong>Results: </strong>Overall, 1641 patients were included from the three Phase 3 clinical trials (802 ceftobiprole; 839 comparators). When stratifying by BMI, ceftobiprole had similar outcomes to the overall ceftobiprole population (80.4%) including patients with obesity (BMI = 30-40 kg/m2) (81.7%). Severe obesity (BMI ≥ 40 kg/m2) was associated with decreased clinical cure rates overall (68.2%) compared with the overall ceftobiprole population, and this was especially noted in the clinically evaluable patient population with CABP receiving ceftobiprole (66.7% in severe obesity versus 86.6% overall). This was also seen in the comparator group (33.3% in severe obesity versus 87.4% overall). However, the number of patients with severe obesity was low in the CABP trial. The safety profile was similar between treatment groups in all studies and not influenced by BMI.</p><p><strong>Conclusions: </strong>This analysis further supports the efficacy and safety of ceftobiprole at current recommended doses in obese patients with SAB, ABSSSI or CABP.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}